A quarterly snapshot of job expansions, reductions and availability in the biotech and pharma sectors.
The second quarter of 2020 saw several pharma company expansions. In April, Baxter International said it would hire up to 2,000 employees globally, including 800 in the United States, in response to greater demand for medical devices due to the coronavirus pandemic.
In June, Fujifilm Diosynth announced a $928 million investment to double biologics production capacity at its Hillerød, Denmark site by 2023. The move comes a year after the contract development and manufacturing arm of the Japanese conglomerate acquired the former Biogen facility for $890 million. The current buildout includes adding six mammalian cell bioreactors, installing a fill/finish production line with an expected capacity of 35 million units per year, and setting up a new packaging line for autoinjectors with automatic labeling. The site has already received a commitment from the COVID-19 Therapeutics Accelerator, which has reserved future manufacturing capacity.
On the negative side, Sage Therapeutics announced a major restructuring following the failure of a phase 3 study. In April, the biotech laid off 340 employees, slightly more than half its workforce.
And in June, Sanofi said it would eliminate 1,700 European jobs, including 1,000 in France, as part of a $1.8 billion cost cutting over the next two years. It also announced it would invest $440 million to build a new vaccine production site in France that would create 200 jobs.
Advertised biotechnology and pharmaceutical sector jobs in the job databases tracked by Nature Biotechnology were down in the second quarter of 2020 (Tables 1 and 2) compared with the previous quarter (Nat. Biotechnol. 38, 651, 2020).
About this article
Cite this article
Francisco, M. Second-quarter biotech job picture. Nat Biotechnol 38, 1003 (2020). https://doi.org/10.1038/s41587-020-0622-0